共 166 条
[1]
Kumar SK(2014)Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients Leukemia 28 1122-1128
[2]
Dispenzieri A(2012)Relapsed/refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance Semin Hematol 49 S3-15
[3]
Lacy MQ(2017)Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma J Clin Oncol 35 1312-1319
[4]
Gertz MA(2017)Novel immunotherapies for multiple myeloma Curr Hematol Malig Rep 12 344-357
[5]
Buadi FK(2013)Chimeric antigen receptor-modified T cells for acute lymphoid leukemia N Engl J Med 368 1509-1518
[6]
Pandey S(2018)Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia N Engl J Med 378 439-448
[7]
Siegel DS(2017)Chimeric antigen receptor T cells in refractory B-cell lymphomas N Engl J Med 377 2545-2554
[8]
van Beurden-Tan CHY(2019)B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma J Clin Invest 129 2210-2221
[9]
Franken MG(2004)BCMA is essential for the survival of long-lived bone marrow plasma cells J Exp Med 199 91-98
[10]
Blommestein HM(2015)Targeting B-cell maturation antigen in multiple myeloma Immunotherapy 7 1187-1199